Combined drug therapy for familial hypercholesterolemia

Area of Science:

• Cardiology
• Metabolic Disorders
• Pharmacology

Background:

• Familial hypercholesterolemia is a genetic disorder leading to high cholesterol.
• Effective management strategies are crucial to reduce cardiovascular risk.

Purpose of the Study:

• To evaluate the efficacy of a combined therapy of cholestyramine and nicotinic acid.
• To assess the impact of this combination on lipid profiles and atherosclerotic risk markers in familial hypercholesterolemia.

Main Methods:

• Six subjects with heterozygous familial hypercholesterolemia were enrolled.
• Treatment involved daily administration of cholestyramine (16 g) and nicotinic acid (3 g).
• Plasma lipid levels, lipoprotein cholesterol, and apolipoprotein levels were measured.

Main Results:

• Combined therapy significantly reduced plasma cholesterol (41%) and triglycerides (37%).
• Low-density lipoprotein cholesterol decreased, while high-density lipoprotein cholesterol increased.
• Apolipoprotein A-I rose by 26%, apolipoprotein B decreased by 31%, and HDL2 increased fourfold.

Conclusions:

• The combination of cholestyramine and nicotinic acid demonstrates significant benefits in managing familial hypercholesterolemia.
• This therapeutic approach favorably alters multiple atherogenic risk indices.
• The findings support the use of this drug combination for treating heterozygous familial hypercholesterolemia.